Your cart
Close Alternative Icon


Learn about Delta-8 THC -- A Light Alternative


Users that want a less intense high while suppressing anxiety may want to try delta-8 products. Delta-8 THC is not as potent as its sister cannabinoid, but it does still produce a mild high. The euphoric feeling produced tends to be less intense than what might be experienced with Delta-9 THC, and you may experience a more clear-headed and energetic. Utilizing CBD with Delta-8 

Delta 8 will not produce the loss of focus that is characteristic of Delta 9.  D8 THC binds to the same receptors, it is 50% less potent, and twice as effective as an anti-nausea when compared to delta-9 THC.  Many users will find that Delta 8 makes them feel more uplifted and motivated. If you have never experienced any form of THC directly, you may want to start small to gauge how it affects you.

This means Delta-8 gives a different kind of high. One that is less potent, but brings a range of unique effects. And in fact, it has often been described as the middle ground between Delta-9 and CBD. CBD has recently exploded in popularity because of these soothing qualities.

The most noticeable difference reported among first-time Delta-8 users was the quality of the high. Compared to cannabis, the effects are fairly mild. It is said to be more alert and energetic, and more relaxing overall. Users will notice the difference in mental state, but it will feel far less hazy. Instead the feelings are more soothing. This is thought to be because of the dual receptor interaction of the molecule. 


Continue reading

What Ailments Qualify For Medical Cannabis in Connecticut?

The CBD Curators can refer qualified patients to local medical marijuana doctors.  Patients must document a qualified ailment.  

Patients in Connecticut diagnosed with one of the following severe, debilitating, or life-threatening medical conditions, are afforded legal protection under the Connecticut Medical Marijuana law, as per House Bill 5389.

For patients under the age of 18 years, the following conditions will effectively qualify:

Connecticut Medical Marijuana Program: Information

To Qualify for Connecticut’s Medical Marijuana Program:

  1. Patients must be 18 years of age. If under 18, Approved Caregiver must accompany and assist you throughout the process.
  2. Patients must be certified by their physician with a Qualifying Condition. (Must be certified before starting the registration process)
  3. Patients must create an account to access the online certification system.
  4. Submit application including your Authorized Caregiver (if applicable), Proof of Identity, Proof of Residency, Photo & $100.00 Application Fee (Caregiver Application is an addition $25.00). Department does not accept Cash Payment. If Mailing Documents, please send to Connecticut Department of Consumer Protection Medical Marijuana Program: 165 Capitol Ave, MS# 88MMP Hartford, CT 06106-1630.
Continue reading

The Deal with Delta-8 THC. Is it legal?

September 02, 2020

With rates for CBD and CBG extracts falling, a new development observed in our August price data was transactions involving delta-8 THC products. Delta-8 THC is not derived from hemp plant material, but synthesized from extracted CBD. It is also a psychoactive cannabinoid; in other words, it will get users “high,” though reportedly in a manner distinct from delta-9 THC. 

Confirmed transactions for delta-8 THC Distillate reported in August by our Price Contributor Network varied widely. However, even the lowest-priced deals for delta-8 THC Distillate settled for more than the assessed prices for both THC Free CBD Distillate and CBG Distillate. Observed asking prices on exchanges and marketplaces exceeded the average confirmed transaction prices by several thousand dollars. Some sellers are also infusing smokable hemp flower with delta-8 THC distillate. Such product is being hawked at high asking prices, easily double or triple those of even higher-priced smokable CBD flower.

Is Delta-8 THC Legal? 

While there is burgeoning interest in delta-8 THC in the U.S. hemp industry, its legal status is uncertain. Additionally, newly-proposed regulations from the Drug Enforcement Agency (DEA) would classify delta-8 THC as a schedule I controlled substance, making it illegal federally and forestalling its market potential. 

The DEA released its Interim Final Rule (IFR) for CBD and other hemp derivatives on August 20. Titled “Implementation of the Agriculture Improvement Act of 2018” in the Federal Register, the proposed rules make several unremarkable technical changes to align DEA regulations and definitions of terms with the 2018 Farm Bill. 

Certain parts of the proposed regulations, however, consist of DEA interpretations of gray areas of the Farm Bill, including those dealing with delta-8 THC and other synthetically-derived forms of THC (tetrahydrocannabinols). As cannabis and hemp business attorney Rod Kight pointed out in a recent blog post, the DEA IFR states, “For synthetically derived tetrahydrocannabinols, the concentration of delta-9 THC is not a determining factor in whether the material is a controlled substance. All synthetically derived tetrahydrocannabinols remain schedule I controlled substances.” 

Consequently, if the DEA IFR was to go into effect as written, then delta-8 THC synthesized from CBD would be illegal and current interest in the compound would be a dead end for businesses. And, while Kight asserts, “It is clear that [delta-8 THC] which is naturally expressed in the hemp plant is not a controlled substance;” he also notes, “Current hemp cultivars do not express [delta-8 THC] in sufficient concentrations or quantities to be economically viable to extract it for commercial purposes.”

As alluded to, the DEA IFR is not final. Public comments on the proposed regulations are being accepted until October 20. 

What Might a Delta-8 THC Market Look Like? 

Until the DEA rules are finalized – or until some enforcement against delta-8 THC production and distribution occurs – Hemp Benchmarks expects interest in the novel cannabinoid to continue to grow. As we pointed out at the outset, prices for CBD and CBG extracts have continued to decline. Many processors are already sitting on sizable inventories of such products, particularly extracted forms of CBD. Given this situation, synthesizing delta-8 THC from one’s surplus inventory of CBD and selling it for significantly higher prices would appear to be an appealing avenue for processors to take. 

However, delta-8 THC’s market potential is hazy at the moment, due both to regulatory uncertainty and the fact that most consumers are unfamiliar with the compound. Since it is psychoactive, the consumer base for delta-8 THC may align more with that for delta-9 THC marijuana, rather than hemp-derived CBD and other non-psychoactive cannabinoids that have a broader appeal. The fact that some businesses are already infusing delta-8 THC Distillate into smokable hemp flower suggests that they are aiming, at least in part, for consumers who already smoke marijuana.

In any case, potential consumers will have to be educated and demand generated, as it is not necessarily latent. Regarding this type of marketing strategy for novel cannabinoids, the sales director of a vertically-integrated hemp-CBD company in Oregon observed to Hemp Benchmarks last month, “the method seems to be [first] isolate the minor [cannabinoid], [then] try to find a market for it. To me that is a little backwards and ends up creating these supply problems we see.” 

He went on to state that he expects an oversupply of delta-8 THC to develop if federal officials do not first move to curtail its production and sale. The CBG market may provide a possible glimpse into the future of delta-8 THC prices. Last year, CBG was hailed by some as the next big thing in the hemp-cannabinoid industry. However, widespread demand has not manifested and CBG product prices have declined precipitously. 

Hemp Benchmarks first began publishing price assessments for CBG Biomass in November 2019. In the nine months since then, the price for CBG Biomass has dropped by 82%. From February 2020 through August 2020, our assessed price for CBG Distillate declined by the same proportion. This price erosion occurred prior to this year’s harvest, which will generate an increased supply of CBG hemp compared to last year. 

Overall, the market potential for delta-8 THC is highly uncertain at the moment, even notwithstanding its hazy legal status. As part of our mission to bring transparency and efficiency to the hemp supply chain, Hemp Benchmarks will publish expanded coverage of delta-8 THC product prices, as well as analysis of market and legal developments, in future reports.   

Continue reading
  • Page 1 of 3